Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.

Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO, TRAIL1 Network Investigators

Open source

DOI: 10.1016/s2213-2600(22)00260-0
Published: 2023 Jan
Container: The Lancet. Respiratory medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-22-00260-0,
  title = {Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.},
  author = {Solomon JJ and Danoff SK and Woodhead FA and Hurwitz S and Maurer R and Glaspole I and Dellaripa PF and Gooptu B and Vassallo R and Cox PG and Flaherty KR and Adamali HI and Gibbons MA and Troy L and Forrest IA and Lasky JA and Spencer LG and Golden J and Scholand MB and Chaudhuri N and Perrella MA and Lynch DA and Chambers DC and Kolb M and Spino C and Raghu G and Goldberg HJ and Rosas IO and TRAIL1 Network Investigators},
  year = {2023},
  journal = {The Lancet. Respiratory medicine},
  doi = {10.1016/s2213-2600(22)00260-0},
  url = {https://doi.org/10.1016/s2213-2600(22)00260-0}
}

RIS

TY  - JOUR
TI  - Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
AU  - Solomon JJ
AU  - Danoff SK
AU  - Woodhead FA
AU  - Hurwitz S
AU  - Maurer R
AU  - Glaspole I
AU  - Dellaripa PF
AU  - Gooptu B
AU  - Vassallo R
AU  - Cox PG
AU  - Flaherty KR
AU  - Adamali HI
AU  - Gibbons MA
AU  - Troy L
AU  - Forrest IA
AU  - Lasky JA
AU  - Spencer LG
AU  - Golden J
AU  - Scholand MB
AU  - Chaudhuri N
AU  - Perrella MA
AU  - Lynch DA
AU  - Chambers DC
AU  - Kolb M
AU  - Spino C
AU  - Raghu G
AU  - Goldberg HJ
AU  - Rosas IO
AU  - TRAIL1 Network Investigators
PY  - 2023
JO  - The Lancet. Respiratory medicine
DO  - 10.1016/s2213-2600(22)00260-0
UR  - https://doi.org/10.1016/s2213-2600(22)00260-0
ER  -

APA

JJ, S., SK, D., FA, W., S, H., R, M., I, G., PF, D., B, G., R, V., PG, C., KR, F., HI, A., MA, G., L, T., IA, F., JA, L., LG, S., J, G., MB, S., N, C., MA, P., DA, L., DC, C., M, K., C, S., G, R., HJ, G., IO, R., & Investigators, T. N. (2023). Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.. The Lancet. Respiratory medicine. https://doi.org/10.1016/s2213-2600(22)00260-0

Source records

pubmed · retrieved 2026-09-25T23:13:40.978Z